Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
18.14
-0.01 (-0.06%)
Jun 29, 2026, 7:03 AM EDT - Market open
Trevi Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 19.41 | 18.91 | 34.1 | 32.4 | 12.59 | 36.83 |
Short-Term Investments | 152.37 | 169.35 | 73.53 | 50.57 | 107.92 | - |
Cash & Short-Term Investments | 171.78 | 188.26 | 107.62 | 82.97 | 120.51 | 36.83 |
Cash Growth | 66.36% | 74.93% | 29.71% | -31.15% | 227.21% | -18.16% |
Other Current Assets | 4.34 | 3.4 | 1.81 | 4.58 | 2.11 | 1.13 |
Total Current Assets | 176.12 | 191.66 | 109.43 | 87.55 | 122.62 | 37.96 |
Net Property, Plant & Equipment | 0.88 | 0.86 | 1.23 | 1.56 | 0.19 | 0.18 |
Other Long-Term Assets | 2.61 | 0.93 | 0.24 | 0.3 | 0.21 | 0.33 |
Total Assets | 179.61 | 193.44 | 110.9 | 89.4 | 123.02 | 38.48 |
Accounts Payable | 2.22 | 3.91 | 3.41 | 1.81 | 2.86 | 2.85 |
Accrued Expenses | 4.58 | 5.53 | 6.81 | 3.71 | 3.52 | 3.81 |
Current Portion of Long-Term Debt | - | - | - | - | 7 | 5.83 |
Current Portion of Leases | 0.32 | 0.31 | 0.29 | 0.31 | 0.03 | 0.12 |
Other Current Liabilities | - | - | - | - | - | 0.11 |
Total Current Liabilities | 7.12 | 9.75 | 10.51 | 5.82 | 13.4 | 12.72 |
Long-Term Debt | - | - | - | - | 2.15 | 8.65 |
Long-Term Leases | 0.36 | 0.45 | 0.75 | 1.03 | 0 | 0.02 |
Other Long-Term Liabilities | - | - | - | - | 0 | - |
Total Long-Term Liabilities | 0.36 | 0.45 | 0.75 | 1.03 | 2.16 | 8.68 |
Total Liabilities | 7.48 | 10.2 | 11.26 | 6.86 | 15.56 | 21.4 |
Common Stock | 0.13 | 0.13 | 0.09 | 0.07 | 0.06 | 0.03 |
Additional Paid-in Capital | 515.19 | 512.77 | 386.53 | 321.64 | 317.59 | 197.96 |
Accumulated Other Comprehensive Income | -0.19 | 0.15 | 0.06 | -0.03 | -0.12 | - |
Retained Earnings | -343 | -329.8 | -287.05 | -239.13 | -210.07 | -180.92 |
Shareholders' Equity | 172.13 | 183.24 | 99.64 | 82.55 | 107.46 | 17.08 |
Total Liabilities & Equity | 179.61 | 193.44 | 110.9 | 89.4 | 123.02 | 38.48 |
Total Debt | 0.68 | 0.75 | 1.03 | 1.34 | 9.18 | 14.63 |
Net Cash (Debt) | 171.1 | 187.51 | 106.59 | 81.63 | 111.33 | 22.2 |
Net Cash Growth | -8.75% | 75.91% | 30.57% | -26.68% | 401.47% | -27.89% |
Net Cash Per Share | 1.21 | 1.39 | 1.04 | 0.82 | 1.73 | 0.97 |
Book Value | 172.13 | 183.24 | 99.64 | 82.55 | 107.46 | 17.08 |
Book Value Per Share | 1.22 | 1.36 | 0.98 | 0.83 | 1.66 | 0.75 |
Tangible Book Value | 172.13 | 183.24 | 99.64 | 82.55 | 107.46 | 17.08 |
Tangible Book Value Per Share | 1.22 | 1.36 | 0.98 | 0.83 | 1.66 | 0.75 |